Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL
Year: 2020
Type: article
Abstract: How to best use tyrosine kinase inhibitors (TKIs) of BCR-ABL after allogeneic stem cell transplantation for Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) is unknown but will almost certainly not be addressed by a definitive randomized trial. Saini and colleagues provide a large body of observational data to reinforce earlier circumstantial evidence favoring prophylactic use of TKIs for at least 2 years posttransplant.
Source: Blood
Authors: Neeraj Saini, David Marin, Celina Ledesma, Ruby Delgado, Gabriela Rondon, Uday R. Popat, Qaiser Bashir, Chitra M. Hosing, Yago Nieto, Amin M. Alousi, Muzaffar H. Qazilbash, Stefan Ciurea, Elizabeth Shpall, Issa Khouri, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Richard E. Champlin, Partow Kebriaei
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W3029202605